SAN DIEGO, June 6, 2016 – ProSciento Inc., a science-driven clinical research organization (CRO) focused exclusively on metabolic diseases, will present study results at this week’s American Diabetes Association (ADA) 76th Scientific Sessions, June 9-14 in New Orleans.
Poster and oral presentations co-authored by ProSciento scientists include:
919-P – Cells Chronically Exposed to the Novel Weekly Insulin HM12470 are Protected Against Desensitization of the Insulin Signaling Cascade
Nina Wronkowitz, Thorsten M. Hartmann, Sven W. Görgens, Daniela Dietze-Schroeder, In Young Choi, Sung Hee Park, Young Mi Lee, Se Chang Kwon, Yeonjoo Kang, Marcus Hompesch, Juergen Eckel, Düsseldorf, Germany, Seoul, Republic of Korea, Chula Vista, CA
947-P – Underlying Mechanisms for Long-Acting Properties of the Novel Weekly Insulin HM12470
Sang Youn Hwang, Jung Kuk Kim, Jin Young Kim, In Young Choi, Marcus Hompesch, Se Chang Kwon, Hwaseong, Seoul, Republic of Korea, Chula Vista, CA
June 11, 11:30 – 1:30 PM
936-P – Double Dose (DD) of Basal Insulin Peglispro (BIL) vs. Glargine (GL) Results in Markedly Lower Incidence of Hypoglycemia in Patients with T2D: IMAGINE 8
Cynthia J. Harris, Thomas Forst, Tim Heise, Leona Plum-Mörschel, Elaine Watkins, Ludi Fan, Parag Garhyan, Niels K. Porksen, Indianapolis, IN, Mainz, Germany, Neuss, Germany, Chula Vista, CA
June 11, 11:30 – 1:30 PM
946-P – A Single-Dose Euglycemic Clamp Study in Subjects with Type 1 Diabetes Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between MK-1293 Insulin Glargine and Originator Insulin Glargine (Lantus)
Michael Crutchlow, John Palcza, Kate Mostoller, Chantal Mahon, April M. Barbour, Michael Marcos, Yang Xu, Linda Morrow, Marcus Hompesch, Kenilworth, NJ, Chula Vista, CA
June 11, 11:30 – 1:30 PM
1026-P – Potent Cholesterol Lowering Effect of the Novel Long-Acting GLP-1/Glucagon Dual Agonist (HM12525A)
Sung Youb Jung, Young Jin Park, Jong Suk Lee, Eun Jung Kim, Young Mi Lee, Young Hoon Kim, Michael Trautmann, Se-Chang Kwon, Seoul, Republic of Korea, Chula Vista, CA
June 11, 11:30 – 1:30 PM
1045-P – Effect of Human Proislet Peptide 2B on ß-Cell Function in Subjects with Metformin-Treated Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
Elaine Watkins, Linda Morrow, Andrew Krentz, Peter Feig, Lori Upham, Joe Reiser, Marcus Hompesch, Chula Vista, CA, Wilmington, DE
June 11, 11:30 – 1:30 PM
1068-P – Underlying Superagonistic Mechanisms of Efpeglenatide in Glyceamic and Weight Loss Potencies
In Young Choi, Sung Hee Park, Mi Jin Moon, Jin Young Kim, Young Mi Lee, Michael Trautmann, Se Chang Kwon, Hwaseong, Seoul, Republic of Korea, Chula Vista, CA
June 11, 11:30 – 1:30 PM
124-LB – Clinical Proof-of-Concept for an Antidiabetic Agent with a Novel Mechanism for Reducing Insulin Resistance
Frank Greenway, Felix Guzman, Raul A. Tamayo, Sin Gon Kim, Elaine Watkins, Min Kyong Moon, Sang Youl Rhee, Moon Kyu Lee, Juan P. Frias, Julio Rosenstock, Choon Hee Chung, Seung Hwan Lee, Bradley Block, Bong Soo Cha, Kwan Woo Lee, William T. Cefalu, Wayne L. Harper, Hyeong Kyu Park, Byung Joon Kim, Andrew G. Reaume, Hee Won Yoo, Baton Rouge, LA, Miami, FL, Seoul, Republic of Korea, Chula Vista, CA, Los Angeles, CA, Dallas, TX, Wonju, Republic of Korea, Oviedo, FL, Suwon, Republic of Korea, Raleigh, NC, Incheon, Seoul, Republic of Korea, Exton, PA
June 12, 12:00 – 2:00 PM
369-OR – The Insulin Secretory Properties of the PGD2-GPR44 Axis, Lack of Translation from Human Islets to Diabetic Patients
Stanko Skrtic, Eva-Marie Andersson, Malin Broberg, Hans Ericsson, Marcus Hompesch, Lars Löfgren, Linda Morrow, Joanna Parkinson, Tina Rydén-Bergsten, Björn Tyrberg, Elaine Watkins, Maria Sörhede-Winzell, Mölndal, Sweden, Chula Vista, CA
June 13, 5:15 – 5:30 PM
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com
For business development inquires:
bd@prosciento.com
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com
(1) U.S. clinical trial data in diabetes, showing that ProSciento’s early phase facility in Chula Vista has completed more Ph I/II T1DM and T2DM studies in the U.S. than any other clinical research site, provided by Citeline’s SiteTrove, a service offered by Informa Pharma Intelligence, April 2016
